Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 23:12:151.
doi: 10.1186/1476-511X-12-151.

The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins

Tian Yang, Ran Peng, Yuan Guo, Li Shen, Shuiping Zhao, Danyan Xu  1
Affiliations

The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins

Tian Yang et al. Lipids Health Dis. .

Abstract

Background: 14,15-Epoxyeicosatrienoic acids (14,15-EETs) generated from arachidonic acid by cytochrome P450 epoxygenases have beneficial effects in certain cardiovascular diseases, and increased 14,15-EET levels protect the cardiovascular system. 14,15-EETs are rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to the corresponding 14,15-dihydroxyeicosatrienoic acids (14,15-DHETs), which are generally less biologically active but more stable metabolite. A functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary heart disease (CHD), and the major CYP2J2 product is 14,15-EETs. 14,15-DHETs can be considered a relevant marker of CYP2J2 activity. Therefore, the aim of the present study was to evaluate the plasma 14,15-DHET levels to reflect the 14,15-EET levels in an indirectly way in patients with CHD, and to highlight the growing body of evidence that 14,15-EETs also play a role in anti-inflammatory and lipid-regulating effects in patients with CHD. This was achieved by investigating the relationship between 14,15-DHETs and high-sensitivity C-reactive protein (hs-CRP) and blood lipoproteins.

Methods: Samples of peripheral venous blood were drawn from 60 patients with CHD and 60 healthy controls. A 14,15-DHET enzyme-linked immunosorbent assay kit (14,15-DHET ELISA kit) was used to measure the plasma 14,15-DHET levels. Hs-CRP, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein-cholesterol levels were measured.

Results: 14,15-DHET levels (2.53 ± 1.60 ng/mL) were significantly higher in patients with CHD as compared with those of the healthy controls (1.65 ± 1.54 ng/mL, P < 0.05). There was a significant positive correlation between 14,15-DHETs and hs-CRP levels (R = 0.286, P = 0.027). However, there was no significant correlation between 14,15-DHETs and blood lipoproteins (all, P > 0.05).

Conclusions: Increased plasma 14,15-DHET levels reflect the decreased of 14,15-EET levels in an indirectly way. Indicated that decreased plasma 14,15-EET levels might be involved in the inflammatory reaction process in atherosclerosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
14,15-DHET levels between the two groups. CHD: Coronary heart disease; 14,15-DHETs: 14,15-dihydroxyeicosatrienoic acids.
Figure 2
Figure 2
Hs-CRP levels between the two groups. CHD: Coronary heart disease; hs-CRP: high-sensitivity C-reactive protein.
Figure 3
Figure 3
Scatter plot of the correlations between 14,15-DHETs and hs-CRP in patients with CHD. 14,15-DHETs: 14,15-dihydroxyeicosatrienoic acids. hs-CRP: high-sensitivity C-reactive protein. The scatter diagram depicts the 14,15-DHETs and hs-CRP concentrations. Spearman correlation analysis revealed a positive correlation between serum 14,15-DHETs and hs-CRP.
See this image and copyright information in PMC

References

    1. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8(10):794–805. doi: 10.1038/nrd2875. - DOI - PMC - PubMed
    1. Michaelis UR, Fisslthaler B. et al. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR) FASEB J. 2003;17(6):770–772. - PubMed
    1. Krötz F, Riexinger T. et al. Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol. 2004;24(3):595–600. doi: 10.1161/01.ATV.0000116219.09040.8c. - DOI - PubMed
    1. Fitzpatrick FA, Ennis MD. et al. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem. 1986;261:15334–15338. - PubMed
    1. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res. 2004;43:55–90. doi: 10.1016/S0163-7827(03)00049-3. - DOI - PubMed

Publication types